Hansoh Pharmaceutical Group (3692) Stock Price, Fundamentals & Analysis
Price
33.52 HKD
-1%
Last trade: Sep 25, 2026, 04:08 PM GMT+8
Updated: Sep 27, 2026, 05:31 PM GMT+8
Price history
Over the past year 3692 traded between 28.56 HKD and 43.36 HKD, closing at 33.52 HKD on Sep 25, 2026.
Key statistics
| Market cap | 203.23B HKD |
|---|---|
| P/E ratio (TTM) | 26 |
| Forward P/E | 25.5 |
| EPS (TTM) | 1.29 CNY |
| Dividend yield | 1.45% |
| Annual dividend | 0.49 HKD |
| Ex-dividend date | Sep 22, 2026 |
| Payout ratio | 35% |
| 52-week range | 28.06 – 44.22 |
| 52-week change | -5.4% |
| Beta | 0.56 |
| Price / book | 4.6 |
| Revenue (TTM) | 15.9B CNY |
| Revenue growth (YoY) | 11.7% |
| Gross margin | 90.5% |
| Operating margin | 44.4% |
| Profit margin | 42% |
| Return on equity | 19.4% |
| Debt / equity | 11.2 |
| Volume | 2,935,886 |
| Average volume | 11,998,171 |
| Next earnings | Aug 26, 2026 |
| Exchange | HKSE |
Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 9,643
- Headquarters
- Shanghai, China
- Website
- hspharm.com
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc.
Overview
What 3692 does
Hansoh Pharmaceutical Group (3692) is an investment holding company listed on the Hong Kong Stock Exchange that researches, develops, produces, and sells pharmaceutical products in China. It operates in the Healthcare sector, specifically in the Drug Manufacturers – Specialty & Generic industry, with products covering anti-infective, central nervous system, oncology, metabolic, and autoimmune therapeutic areas. The company is headquartered in Shanghai, China, and employs 9,643 people. It is part of the broader Hong Kong-listed healthcare ecosystem alongside peers such as Sinopharm Group (1099) and CSPC Pharmaceutical Group (1093).
Key numbers explained
- 33.52 HKD is the current share price, representing the latest trading value of one share.
- The trailing P/E ratio of 26 shows the price investors pay per unit of the last 12 months’ earnings; a higher P/E ratio can signal higher growth expectations.
- The forward P/E ratio of 25.5 uses expected future earnings, offering a view of valuation based on analyst estimates.
- 1.29 CNY is the trailing 12-month earnings per share (EPS), indicating the portion of profit attributable to each share.
- The dividend yield of 1.45% measures the annual dividend income relative to the share price; the dividend yield is a common way to compare income across stocks.
- 11.7% revenue growth year over year shows how quickly the company’s top line has expanded over the trailing 12 months.
- A profit margin of 42% and operating margin of 44.4% reflect how much of each revenue yuan remains as profit after costs and operating expenses.
- Beta of 0.56 suggests the stock has historically been less volatile than the overall market.
What to watch
- Earnings reports and the nextEarningsDate of 26 aug. 2026 can drive short-term price moves as the market digests results and guidance.
- The exDividendDate of 22 sept. 2026 is the key date for dividend eligibility; investors typically need to own the stock before this date.
- The 52-week range of 28.06 – 44.22 provides context for where the current price sits relative to recent highs and lows.
- Revenue growth, margins, and debt levels are standard factors that analysts monitor for any large-cap healthcare stock.
- As a Hong Kong-listed stock, Hansoh Pharmaceutical Group (3692) can be influenced by broader market moves tracked by indices such as the Hang Seng.
Latest news & filings
No recent headlines.
Frequently asked questions
Does 3692 pay a dividend?
Yes. Hansoh Pharmaceutical Group (3692) has a dividend yield of 1.45%, and 35% of earnings are paid out as dividends, with the next ex-dividend date on 22 sept. 2026.
What is the 3692 P/E ratio?
The trailing P/E ratio is 26, and the forward P/E ratio based on expected earnings is 25.5.
Where can I buy 3692?
Hansoh Pharmaceutical Group (3692) trades on the Hong Kong Stock Exchange. You can buy it through any broker that offers access to Hong Kong-listed stocks.
What sector and industry does 3692 belong to?
It is in the Healthcare sector and the Drug Manufacturers – Specialty & Generic industry.
How big is Hansoh Pharmaceutical Group?
The company has a market cap of 203.23 mld. HKD, 9,643 employees, and trailing 12-month revenue of 15.9 mld. CNY.
Related
More on 3692
Track 3692 in your portfolio
Hold 3692 at XTB, IBKR, Tradeville, Revolut or Trading 212? InvestPane brings every broker into one dashboard — allocation, performance and dividends in one place.
Start free